Monitoring the Safety of Pioglitazone
Tóm tắt
Background: Pioglitazone is an antidiabetic drug that targets insulin resistance in patients with type 2 diabetes mellitus by stimulating the peroxisome proliferatoractivated receptor (PPAR)-#$. Pioglitazone belongs to a class of drugs called thiazolidinediones (TZDs) and was launched in the UK in November 2000.
Objective: To monitor, using prescription-event monitoring, the post-marketing safety of pioglitazone, which is prescribed in primary care in England.
Methods: An observational cohort study in which patients were identified from dispensed prescriptions issued by primary-care physicians/general practitioners (GPs) between November 2000 and June 2001. Information on demographics, the use of pioglitazone, clinical event data, events suspected as adverse drug reactions, reasons for stopping the drug and cause of death (if appropriate) were collected using questionnaires posted to GPs at least 8 months after the date of first prescription for each patient. Event incidence densities (IDs) [number of first reports of an event/1000 patient-months of exposure] were calculated.
Results: The cohort comprised 12 772 patients (median age 62 years); 53.1% were males. The most frequent starting daily dose of pioglitazone was either 15 mg or 30 mg (n = 10 298). Pioglitazone/metformin was the most frequently used combination reported (n = 4029). Of the 3690 patients who stopped treatment, 1143 stopped due to reasons related to poor glycaemic control. ’Oedema/ fluid retention’ (n = 121) and ’weight gain’ (n = 118) also appeared high on the list of reasons for discontinuing. ’Malaise/lassitude’ and ’nausea/vomiting’ were the most frequently reported suspected adverse drug reactions (ADRs) associated with pioglitazone. Specific clinical events considered as early onset events with pioglitazone were: ’malaise/lassitude’, ’nausea/vomiting’, ’dizziness’, ’headache/ migraine’, ’diarrhoea’, ’weight gain’ and ’abnormal liver function test’.
Conclusion: Pioglitazone was considered to be a reasonably well tolerated drug, with the main reasons for discontinuing being related to the drug not being effective. The frequency of individual ADRs reported in this study did not exceed the frequency in the summary of product characteristics (SPC) for pioglitazone. However, amongst the frequently reported suspected ADRs, ’nausea/vomiting’ and ’diarrhoea’ are not listed in the SPC. Further research is required to assess whether the risk of myocardial infarction and deaths due to cardiovascular causes is a class effect of the thiazolidinediones. Results from this study should be taken into account with other clinical and pharmacoepidemiological studies.
Tài liệu tham khảo
Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels 2001; 7(4): 249–58
Wise J. Diabetes drug withdrawn after reports of hepatic events [letter]. BMJ 1997 Dec 13; 315(7122): 1564
Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001; 24(12): 873–88
Tolman KG. Thiazolidinedione hepatotoxicity: a class effect? Int J Clin Pract Suppl 2000 Oct; (113): 29-34
Takeda Europe R & D Centre Limited. Summary of Product Characteristics for Actos (pioglitazone hydrochloride); 2000 Oct
May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002 Mar 19; 136(6): 449–52
Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy [letter]. Ann Intern Med 2002 Nov 19; 137(10): 857
Maeda K. Hepatocellular injury in a patient receiving pioglitazone [letter]. Ann Intern Med 2001 Aug 21; 135(4): 306
Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002 Feb; 97(2): 502–3
Nagasaka S, Abe T, Kawakami A, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med 2002 Apr; 19(4): 347–8
Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone [letter]. BMJ 2004 Aug 21; 329(7463): 429
Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs 2006; 6(5): 297–304
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglit Azone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89
Jamieson A, Abousleiman Y. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2004 Apr; 79(4): 571–7
Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003 Sep; 78(9): 1088–91
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 Jun 14; 356(24): 2457–71
Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep 12; 298(10): 1180–8
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep; 21(9): 1414–31
Shakir S. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 203–16
Strom B. Sample size considerations for pharmacoepidemiology studies. In: Strom B, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons, 1994
Machin D, Campbell M, Fayers P, et al. Chapter 7. Post marketing surveillance. Table 7. 1. Sample sizes required to observe a single adverse reaction with a given probability and anticipated incidence. In: Machin D, editor. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science Ltd, 1997: 150
CIOMS W. International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2002 [online]. Available from URL: http://www.cioms.ch/frame_guidelines_nov_2002.htm [Accessed 2008 Jul 26]
Royal College of Physicians of London. Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects. 3rd ed. London: Royal College of Physicians, 1996
Department of Health. Supplementary operational guidelines for NHS Research Ethics Committees November 2000. Multi-centre research in the NHS the process of ethical review when there is no local researcher [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4006696.[Accessed 2008 Jul 26]
Brettenthaler N, De GC, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004 Aug; 89(8): 3835–40
Prasithsirikul W, Bunnag P. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. J Med Assoc Thai 2004 Feb; 87(2): 166–72
Takeda UK Limited. Summary of Product Characteristics for Actos (pioglitazone hydrochloride), 2007 Aug [online]. Available from URL: http://emc.medicines.org.uk/industry/default.asp [Accessed 2008 Aug 19]
Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007 May 1; 49(17): 1772–80
Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007 Oct; 16(10): 1065–71
Larsen WJ. Human embryology. 2nd ed. New York: Churchill Livingstone Inc., 1997: 62–3
Reece EA, Hobbins JC. Diabetic embryopathy: pathogenesis, prenatal diagnosis and prevention. Obstet Gynecol Surv 1986 Jun; 41(6): 325–35